Abstract: The invention relates to the field of cancer immunotherapy by employing CD4+ cell populations, CD8+ cell populations, or a combination thereof, comprising bicistronic inhibitory chimeric antigen receptor (iCAR)/activating chimeric antigen receptor (aCAR) constructs for use in cancer treatment therapies.

Abstract: An isolated polypeptide comprising an amino acid sequence corresponding to the amino acid residues forming a full or partial ?-helical domain, the hinge domain, the ?-triple spiral domain and a full or partial globular head domain of an avian reovirus sigma C protein, and lacking the amino acid sequence that is N-terminal to said ?-helical domain is provided. Furthermore, a vaccine comprising, or a viral vector expressing, at least one of the isolated polypeptides of the present invention is provided.

Abstract: The present invention relates to lyso-diacylglyceryltrimethylhomoserine (lyso- DGTS) or derivatives thereof for use in the treatment of atherosclerotic cardiovascular disease, and further provides particular such lyso-DGTS derivatives.

Abstract: The present invention provides a method of identifying a target for preparing an inhibitory chimeric antigen receptor (iCAR) or a protective chimeric antigen receptor (pCAR) capable of preventing or attenuating undesired activation of an effector immune cell. Also provided are a list of iCAR targets, as well as vectors and transduced effector immune cells comprising the nucleic acid molecule and methods for treatment of cancer comprising administering the transduced effector immune cells are further provided.

Abstract: The present invention relates to lyso-diacylglyceryltrimethylhomoserine (lyso-DGTS) or derivatives thereof for use in the treatment of atherosclerotic cardiovascular disease, and further provides particular such lyso-DGTS derivatives.

Abstract: An isolated polypeptide comprising an amino acid sequence corresponding to the amino acid residues forming a full or partial ?-helical domain, the hinge domain, the ?-triple spiral domain and a full or partial globular head domain of an avian reovirus sigma C protein, and lacking the amino acid sequence that is N-terminal to said ?-helical domain is provided. Furthermore, a vaccine comprising, or a viral vector expressing, at least one of the isolated polypeptides of the present invention is provided.

Abstract: Nucleic acid molecules comprising a nucleotide sequence encoding an activating chimeric antigen receptor (aCARs) are provided, said aCARs comprising (i) an extracellular binding-domain specifically binding an antigen selected from an antigen of the commensal gut microflora and a self-cell surface antigen specific to the lamina propria (LP) or submucosa of the gastrointestinal tract; (ii) a transmembrane domain; (iii) an intracellular domain including at least one signal transduction element that activates and/or co-stimulates a T cell; and optionally (iv) a stalk region linking the extracellular domain and the transmembrane domain.

Abstract: The present invention relates to a method for production of potable water by removal from water of an aqueous environment selected from a river, a lake, a reservoir, a pond, a stream, groundwater, spring water, surface water, or combinations thereof, organic colloidal particles of biocontaminants. The method comprises applying to the water at least one nanocomposite consisting of a mineral platform, which is denser than water, and at least one polyelectrolyte polymer adsorbed to said mineral platform with charge opposite to the charge of the colloidal particles.

Abstract: A system for treatment of a polluted effluent, includes an outer chamber configured to treat the polluted effluent in mixture with a purification slurry including particles of one or more catalysts and/or organoclays, or a mixture thereof. The outer chamber includes (i) a stirring unit consisting of an engine and a stirrer, configured to mix the polluted effluent and the purification slurry to prevent the particles from sinking without causing a turbulence, (ii) a membrane located at the top of the outer chamber through which a treated effluent passes, while preventing the particles of one or more catalysts and/or organoclays from exiting the outer chamber together with the treated effluent, (iii) a membrane cleaning system configured to remove and collect the particles of one or more catalysts and/or organoclays accumulated on the membrane, and re-introducing the particles back to the bottom of the outer chamber.

Abstract: A protein, e.g. an antibody, coated with a non-immunogenic molecule selected from an amino-monosaccharide-biotin adduct or a monosaccharide-biotin adduct is disclosed, wherein the coated protein, which has diminished immunogenicity relative to the uncoated protein and intact biological activity, enables, for example, cross-species vaccination.

Abstract: A vitamin D2-enriched biomass of an edible fungus, extracts and compositions thereof are provided, for use in delaying onset of, treating, ameliorating or protecting from an immune-related or inflammatory related disease, disorder or condition, wherein the level of vitamin D2 in said biomass is at least 80 IU/gr.

Abstract: An isolated polypeptide comprising an amino acid sequence corresponding to the amino acid residues forming a full or partial ?-helical domain, the hinge domain, the ?-triple spiral domain and a full or partial globular head domain of an avian reovirus sigma C protein, and lacking the amino acid sequence that is N-terminal to said ?-helical domain is provided. Furthermore, a vaccine comprising, or a viral vector expressing, at least one of the isolated polypeptides of the present invention is provided.

Abstract: A method for pretreatment of wastewater or recreational water with substantial reduction of total suspended solids and turbidity in a very short time is provided comprising treatment with nanocomposites and a bridging agent.

Abstract: The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.

Abstract: A single step pretreatment of wastewater or recreational water is provided comprising treatment with nanocomposites consisting of an anchoring particle such as a clay mineral and one or more polymers.

Abstract: The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.

Abstract: A protein, e.g. an antibody, coated with a non-immunogenic molecule selected from an amino-monosaccharide-biotin adduct or a monosaccharide-biotin adduct is disclosed, wherein the coated protein, which has diminished immunogenicity relative to the uncoated protein and intact biological activity, enables, for example, cross-species vaccination.

Abstract: A single step pretreatment of wastewater or recreational water is provided comprising treatment with nanocomposites consisting of an anchoring particle such as a clay mineral and one or more polymers.

Abstract: Pharmaceutical or cosmetic compositions including cruciferous plant extract or isothiocyanates such as 4-methyl-thio-butyl-isothiocyanate which are useful for treating psoriasis are provided.

Abstract: A protein covalently linked to, or coated with, a non-immunogenic molecule selected from an amino monosaccharide-biotin adduct or a monosaccharide-biotin adduct is disclosed, wherein the coated protein, which has diminished immuno-genicity relative to the uncoated protein and intact biological activity, enables, for example, cross-species vaccination